You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriamterene
Accession NumberDB00384  (APRD00079)
TypeSmall Molecule
GroupsApproved
DescriptionA pteridine that is used as a mild diuretic. [PubChem]
Structure
Thumb
Synonyms
6-phenylpteridine-2,4,7-triamine
Dyrenium
Teridin
Triamteren
Triamtérène
Triamterene
Triamtereno
Triamterenum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DyreniumCapsule50 mg/1OralWell Spring Pharmaceutical Corporation1999-10-01Not applicableUs
DyreniumCapsule100 mg/1OralWell Spring Pharmaceutical Corporation1999-01-01Not applicableUs
DyreniumCapsule50 mg/1OralConcordia Pharmaceuticals Inc.1999-10-01Not applicableUs
DyreniumCapsule50 mg/1OralCarilion Materials Management1999-10-01Not applicableUs
DyreniumCapsule100 mg/1OralConcordia Pharmaceuticals Inc.1999-01-01Not applicableUs
Dyrenium 100Tablet100 mgOralGlaxosmithkline Inc1992-12-312002-07-03Canada
Dyrenium 50Tablet50 mgOralGlaxosmithkline Inc1992-12-312002-07-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiuterenKotobuki Seiyaku
DytacMercury
RiyazineCiiphar
TriterenKyoto Yakuhin
UrinisYing Yuan
Brand mixtures
NameLabellerIngredients
Apo TriazideApotex Inc
DyazideCardinal Health
Dyazide TabSmithkline Beecham Pharma Division Of Smithkline Beecham Inc
MaxzideMylan Pharmaceuticals Inc.
Maxzide-25Mylan Pharmaceuticals Inc.
Nu-triazide Tab 50 Mg/25 mgNu Pharm Inc
Penta-triamterene Hctz TabletsPentapharm Ltd.
Pro-triazidePro Doc Limitee
Riva-zide 50/25mg TabletsLaboratoire Riva Inc
Teva-triamterene/hctzTeva Canada Limited
Triamterene and HydrochlorothiazideKAISER FOUNDATION HOSPITALS
Triamterene HydrochlorothiazideKAISER FOUNDATION HOSPITALS
SaltsNot Available
Categories
UNIIWS821Z52LQ
CAS number396-01-0
WeightAverage: 253.2626
Monoisotopic: 253.107593387
Chemical FormulaC12H11N7
InChI KeyFNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
IUPAC Name
6-phenylpteridine-2,4,7-triamine
SMILES
NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.
Structured Indications
PharmacodynamicsTriamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.
Mechanism of actionTriamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.
TargetKindPharmacological actionActionsOrganismUniProt ID
Amiloride-sensitive sodium channel subunit gammaProteinyes
inhibitor
HumanP51170 details
Amiloride-sensitive sodium channel subunit alphaProteinyes
inhibitor
HumanP37088 details
Amiloride-sensitive sodium channel subunit betaProteinyes
inhibitor
HumanP51168 details
Amiloride-sensitive sodium channel subunit deltaProteinunknown
inhibitor
HumanP51172 details
Related Articles
AbsorptionRapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
Volume of distributionNot Available
Protein binding55-67% (93% for the OH-TA-ester metabolite)
Metabolism

Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.

Route of eliminationNot Available
Half life255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.
Clearance
  • 4.5 l/min [total plasma clearance]
  • 0.22 l/kg [renal plasma clearance]
ToxicityIn the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Triamterene Action PathwayDrug actionSMP00132
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Triamterene can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Triamterene.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Triamterene.Investigational
AcetyldigitoxinThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Triamterene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triamterene.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triamterene.Experimental, Illicit
AmifostineThe risk or severity of adverse effects can be increased when Triamterene is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Triamterene is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.Approved
Ammonium chlorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Ammonium chloride.Approved, Vet Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Triamterene.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Triamterene is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Triamterene is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Triamterene.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Triamterene.Approved
AnvirzelThe therapeutic efficacy of Anvirzel can be decreased when used in combination with Triamterene.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Triamterene is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Triamterene.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Triamterene.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Triamterene.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Triamterene is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Triamterene is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Triamterene.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Triamterene.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Triamterene is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Triamterene can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Triamterene.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Triamterene.Experimental
BarbitalBarbital may increase the hypotensive activities of Triamterene.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Triamterene.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.Approved
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Triamterene.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Triamterene is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Triamterene.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Triamterene.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Triamterene.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.Approved
BortezomibThe metabolism of Triamterene can be decreased when combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Triamterene is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Triamterene.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Triamterene is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Triamterene.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Triamterene is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Triamterene can be decreased when combined with Caffeine.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Triamterene.Approved
CandesartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Candesartan.Approved
CandoxatrilTriamterene may increase the hyperkalemic activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Captopril.Approved
CarbamazepineThe metabolism of Triamterene can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Triamterene is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triamterene.Illicit, Vet Approved
CarprofenCarprofen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Triamterene is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Triamterene.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Triamterene.Approved
ChloroquineChloroquine may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Triamterene.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilnidipine.Approved
CitalopramThe metabolism of Triamterene can be decreased when combined with Citalopram.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.Approved
ClonixinClonixin may decrease the antihypertensive activities of Triamterene.Approved
ClotrimazoleThe metabolism of Triamterene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Triamterene is combined with Conivaptan.Approved, Investigational
CurcuminCurcumin may decrease the antihypertensive activities of Triamterene.Investigational
CyclosporineTriamterene may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Triamterene can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Triamterene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Triamterene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.Approved
DeferasiroxThe serum concentration of Triamterene can be increased when it is combined with Deferasirox.Approved, Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Triamterene is combined with Desflurane.Approved
DeslanosideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triamterene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triamterene.Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Triamterene.Approved
DigitoxinThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.Approved
DigoxinThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triamterene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Triamterene.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Triamterene.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triamterene.Investigational
DrospirenoneDrospirenone may increase the hyperkalemic activities of Triamterene.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Triamterene.Approved
DuloxetineTriamterene may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Triamterene.Investigational
E6201E6201 may decrease the antihypertensive activities of Triamterene.Investigational
EbselenEbselen may decrease the antihypertensive activities of Triamterene.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Enalapril.Approved, Vet Approved
EnalaprilatTriamterene may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Triamterene.Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Triamterene.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Triamterene.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Triamterene is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Triamterene.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Triamterene.Approved, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Triamterene.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Triamterene.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triamterene.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Triamterene.Approved
exisulindexisulind may decrease the antihypertensive activities of Triamterene.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Triamterene.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Triamterene is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Triamterene.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Fimasartan.Approved
FloctafenineFloctafenine may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Triamterene.Vet Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Triamterene.Approved, Investigational
FluvoxamineThe metabolism of Triamterene can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Triamterene.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Triamterene is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Triamterene.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triamterene.Approved, Illicit
HexobarbitalHexobarbital may increase the hypotensive activities of Triamterene.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Triamterene.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Triamterene.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.Approved, Illicit
IbuprofenIbuprofen may decrease the antihypertensive activities of Triamterene.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Triamterene.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Triamterene.Approved
IloprostThe risk or severity of adverse effects can be increased when Triamterene is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Triamterene is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.Approved
IndomethacinIndomethacin may increase the nephrotoxic activities of Triamterene.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Triamterene.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Triamterene is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Triamterene is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Triamterene.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Triamterene is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Triamterene.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Triamterene.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triamterene.Approved
KetoprofenKetoprofen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Triamterene.Approved
LabetalolThe risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Lacidipine.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Triamterene.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Triamterene is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Triamterene is combined with Levobupivacaine.Approved
LevodopaTriamterene may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Triamterene is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Triamterene can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Triamterene.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triamterene.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Lofexidine.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Triamterene.Approved
LosartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Triamterene.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Triamterene.Approved
MannitolThe risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Triamterene.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Triamterene.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Triamterene.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Triamterene.Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triamterene.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Triamterene.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Triamterene.Approved
MetipranololThe risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Triamterene.Approved, Investigational
MexiletineThe metabolism of Triamterene can be decreased when combined with Mexiletine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Triamterene.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Triamterene.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Triamterene.Approved
NabiloneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Triamterene.Approved
NadololThe risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Triamterene.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Triamterene.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Triamterene.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Triamterene.Investigational
NebivololThe risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.Approved, Investigational
NepafenacNepafenac may decrease the antihypertensive activities of Triamterene.Approved
NesiritideThe risk or severity of adverse effects can be increased when Triamterene is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Triamterene can be decreased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Triamterene.Approved
NifedipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Triamterene.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Triamterene.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Triamterene.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triamterene.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Triamterene is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triamterene.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Triamterene.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Triamterene.Approved
OmapatrilatTriamterene may increase the hyperkalemic activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triamterene.Approved, Illicit
OrgoteinOrgotein may decrease the antihypertensive activities of Triamterene.Vet Approved
OsimertinibThe serum concentration of Triamterene can be decreased when it is combined with Osimertinib.Approved
OuabainThe therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Triamterene.Approved
OxprenololThe risk or severity of adverse effects can be increased when Triamterene is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Triamterene.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Triamterene is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Triamterene.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Triamterene.Approved
Peginterferon alfa-2bThe serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Triamterene is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Triamterene.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Triamterene is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Triamterene can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Triamterene is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Triamterene is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Triamterene is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Triamterene is combined with Pipamperone.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Triamterene.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Triamterene.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Triamterene.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Triamterene is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.Approved
PrimidoneThe metabolism of Triamterene can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Triamterene.Approved
PropofolThe risk or severity of adverse effects can be increased when Triamterene is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.Approved, Investigational
PTC299PTC299 may decrease the antihypertensive activities of Triamterene.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Quinapril.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Triamterene.Approved
RasagilineThe risk or severity of adverse effects can be increased when Triamterene is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.Approved
RescinnamineTriamterene may increase the hyperkalemic activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triamterene.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Triamterene.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Triamterene.Approved
RifampicinThe metabolism of Triamterene can be increased when combined with Rifampicin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Triamterene is combined with Riociguat.Approved
RisperidoneTriamterene may increase the hypotensive activities of Risperidone.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Triamterene.Investigational, Withdrawn
RopiniroleThe metabolism of Triamterene can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Triamterene is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Triamterene is combined with Rotigotine.Approved
SacubitrilSacubitril may increase the hyperkalemic activities of Triamterene.Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Triamterene.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Triamterene.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Triamterene.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Triamterene.Experimental
SaralasinSaralasin may increase the hyperkalemic activities of Triamterene.Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Triamterene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Triamterene is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Triamterene.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Triamterene is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe metabolism of Triamterene can be decreased when combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Triamterene is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.Approved
SpiraprilTriamterene may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneTriamterene may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Triamterene.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Triamterene is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Triamterene.Approved
SulindacSulindac may decrease the antihypertensive activities of Triamterene.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Triamterene.Approved, Withdrawn
TacrolimusTriamterene may increase the hyperkalemic activities of Tacrolimus.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.Approved
TasosartanTasosartan may increase the hyperkalemic activities of Triamterene.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Telmisartan.Approved, Investigational
TemocaprilTriamterene may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenofovirThe metabolism of Triamterene can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Triamterene.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Triamterene.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.Approved
TeriflunomideThe serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Triamterene is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Triamterene can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Triamterene.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Triamterene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Triamterene is combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Triamterene.Approved
TiclopidineThe metabolism of Triamterene can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Triamterene.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Triamterene.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Triamterene.Approved
TizanidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Triamterene is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Triamterene is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Triamterene.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Triamterene.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Triamterene.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Triamterene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Triamterene is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Triamterene is combined with Tretinoin.Approved, Investigational, Nutraceutical
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Triamterene.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Triamterene.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.Approved, Investigational
VemurafenibThe serum concentration of Triamterene can be increased when it is combined with Vemurafenib.Approved
VerapamilThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Triamterene.Approved
ZileutonZileuton may decrease the antihypertensive activities of Triamterene.Approved, Investigational, Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Triamterene.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Frederic J. Nugent, John K. C. Yen, “Process for preparing the combination products of triamterene and hydrochlorothiazide.” U.S. Patent US4804540, issued July, 1987.

US4804540
General References
  1. Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. [PubMed:6628507 ]
External Links
ATC CodesC03DB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8735
Caco-2 permeable+0.7017
P-glycoprotein substrateNon-substrate0.6269
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8437
CYP450 2C9 substrateNon-substrate0.8949
CYP450 2D6 substrateNon-substrate0.8892
CYP450 3A4 substrateNon-substrate0.7542
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6161
Ames testNon AMES toxic0.8934
CarcinogenicityNon-carcinogens0.9092
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.7706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wellspring pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral50 mg/1
TabletOral100 mg
TabletOral50 mg
CapsuleOral
TabletOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point316 °CPhysProp
water solubility48.2 mg/LNot Available
logP0.98HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.963 mg/mLALOGPS
logP1.21ALOGPS
logP1.11ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)3.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity75.13 m3·mol-1ChemAxon
Polarizability25.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - CI-B (Unknown) , Positivesplash10-0udi-0090000000-c8bbcf103f5a3fdfebb5View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form pyrimido(4,5-b)pyrazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPteridines and derivatives
Sub ClassNot Available
Direct ParentPteridines and derivatives
Alternative Parents
Substituents
  • Pteridine
  • Aminopyrimidine
  • Aminopyrazine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Pyrazine
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1G
Uniprot ID:
P51170
Molecular Weight:
74269.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214 ]
  4. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  5. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1A
Uniprot ID:
P37088
Molecular Weight:
75703.08 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1B
Uniprot ID:
P51168
Molecular Weight:
72658.485 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ligand-gated sodium channel activity
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.
Gene Name:
SCNN1D
Uniprot ID:
P51172
Molecular Weight:
70214.195 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23